Itching, not pain, is the symptom most people with vulvar cancer notice first. Persistent vulvar pruritus (itching) is the most commonly reported and longest-lasting symptom, followed by bleeding, discharge, difficulty urinating, and only then pain. That said, pain does become a significant part of the picture as the disease progresses or after treatment begins, and the nature of that pain varies depending on what structures are involved.
What Early Vulvar Cancer Actually Feels Like
The mismatch between expectation and reality trips up a lot of people. Because the word “cancer” triggers thoughts of pain, many assume that vulvar cancer announces itself with obvious discomfort. In practice, the earliest sign is usually a persistent itch that does not respond to the usual over-the-counter creams. Some people also notice a visible change: a lump, a thickened patch of skin, or an ulcer that does not heal. Bleeding unrelated to menstruation and unusual discharge are other early signals.1PubMed Central. Vulvar cancer: epidemiology, clinical presentation, and management options
Some vulvar cancers are entirely asymptomatic and found only during a routine gynecological exam. Others present with pain early on, but that tends to be the exception rather than the rule. A 2021 clinical update noted that while vulvar cancer can be asymptomatic, most patients present with either itching, pain, or a noticeable lump or ulcer.2International Journal of Gynecology & Obstetrics. Cancer of the vulva: 2021 update The key takeaway is that waiting for pain before seeking evaluation is a mistake. Itching, color changes, or a sore that lingers for weeks all warrant a visit to a clinician.
Why Diagnosis Often Takes Months Longer Than It Should
One of the more frustrating aspects of vulvar cancer is that it frequently gets misdiagnosed as something benign for months before anyone performs a biopsy. A study examining diagnostic delays found that women who had initially been diagnosed with vulvar or vaginal inflammation waited an average of 328 days before vulvar cancer was identified. Women first told they had noninflammatory vulvar conditions like atrophy or cysts waited around 300 days, and those initially diagnosed with Bartholin’s gland problems waited about 186 days.3PubMed Central. Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in gynecological practices
That is roughly six months to nearly a year of delay, on average. The reasons are partly medical and partly social. Vulvar cancer is uncommon enough that many clinicians do not immediately suspect it, especially in younger patients. There is also significant overlap between its symptoms and those of common conditions like lichen sclerosus, yeast infections, and contact dermatitis. On the patient side, embarrassment and discomfort discussing genital symptoms contribute to later presentation. In a study of younger women with vulvar cancer, symptoms had been present for more than twelve months in nearly half the patients before diagnosis, though interestingly, the duration of symptoms did not correlate with more advanced staging or positive lymph nodes.3PubMed Central. Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in gynecological practices
Prior vulvar inflammation was itself associated with higher risk of vulvar cancer, with an odds ratio of about 2.3 for vaginal and vulvar inflammation and about 5.4 for noninflammatory vulvar disorders like atrophy and hypertrophy. These conditions are not just misdiagnoses that delay treatment; some of them may actually be part of the pathway to cancer.
Lichen Sclerosus and the Road to Vulvar Cancer
Lichen sclerosus deserves special attention because it is one of the best-established precursor conditions. It is a chronic inflammatory skin condition that causes white, thinning patches on the vulva, often accompanied by intense itching and pain during sex. A significant minority of vulvar cancers arise from tissue affected by lichen sclerosus, particularly the HPV-negative subtype.
Women with lichen sclerosus also have higher rates of other pain-related conditions. Research comparing lichen sclerosus patients to controls found markedly higher rates of painful intercourse, with a twenty-fold increased risk, and of interstitial cystitis, with a five-fold increased risk.4PubMed Central. Comorbidity of Urogynecological and Gastrointestinal Disorders in Female Patients With Lichen Sclerosus This means that for women who develop vulvar cancer on the background of lichen sclerosus, pain may already be part of their daily experience before the cancer itself causes any. Disentangling cancer pain from pre-existing chronic vulvar pain is a real clinical challenge in this population.
How Vulvar Cancer Is Staged
Vulvar cancer is staged using the FIGO system, which was most recently revised in 2021. The staging reflects how large the tumor is, how deep it has grown, and whether it has spread to nearby lymph nodes or distant organs. The 2021 revision reorganized stages into two substages in Stage I, no substages in Stage II, three substages in Stage III, and two substages in Stage IV. It also updated the definition of depth of invasion and incorporated cross-sectional imaging findings into staging decisions.5PubMed Central. FIGO staging for carcinoma of the vulva: 2021 revision
In practical terms, here is what each stage broadly means:
- Stage I: The cancer is confined to the vulva or perineum and has not spread to lymph nodes. Substages reflect the size and depth of invasion.
- Stage II: The tumor has grown into nearby structures like the lower urethra, lower vagina, or anus, but lymph nodes remain clear.
- Stage III: Lymph nodes in the groin are involved. Substages depend on the number and size of lymph node metastases and whether the nodes have spread beyond their capsule.
- Stage IV: The cancer has invaded the upper urethra, bladder, rectum, or pelvic bone (Stage IVA), or has spread to distant sites (Stage IVB).
Stage matters enormously for prognosis and, as it turns out, for the pain experience as well.
When and Why Pain Becomes Significant
Pain in vulvar cancer generally tracks with disease progression, but the relationship is not perfectly linear. Early-stage cancers can cause local soreness, burning, or stinging, especially if the tumor ulcerates or sits in an area that experiences friction. But the real shift happens when the cancer grows deep enough to involve nerves, muscles, or bone.
Pelvic cancers in general produce several distinct types of pain. Somatic pain comes from direct tumor invasion into skin, muscles, joints, and bone. Neuropathic pain occurs when the tumor infiltrates nerve trunks, and this affects roughly six in ten patients with pelvic soft-tissue cancers. Nerve infiltration can cause lumbosacral plexopathies, burning sensations (causalgia), and numbness or abnormal sensory responses in the perineum and lower limbs.6Wiley Online Library. Pelvic cancer pain These neuropathic symptoms are particularly difficult to manage because they do not respond well to standard painkillers.
Advanced vulvar cancer can also cause what is essentially mechanical pain from tumor bulk pressing on or eroding into the urethra, vagina, rectum, or pubic bone. Sitting, walking, and wearing clothing can all become painful. At Stage IVA and IVB, pain from distant metastases adds another layer of suffering.
Treatment-Related Pain and Complications
Treating vulvar cancer often introduces its own set of painful complications, sometimes lasting well beyond the acute recovery period. Surgery, radiation, and chemotherapy each carry distinct risks.
Surgical Complications
The standard surgical approaches range from wide local excision for small tumors to radical vulvectomy for more extensive disease, often combined with removal of groin lymph nodes. Wound breakdown and infection are common complications, particularly with more radical procedures. One study comparing radical vulvectomy to modified approaches found that wound breakdown occurred in about 47% of radical vulvectomy patients versus 20% of those who had modified surgery, and lymphedema affected 48% of the radical group compared to 12% of the modified group.7PubMed. Wound complications in patients with carcinoma of the vulva. Comparison between radical and modified vulvectomies
Lymphedema of the lower limbs is one of the most dreaded long-term effects. A systematic review found that women who had full groin lymph node dissection were about five times more likely to develop lower-limb lymphedema than those who had a less extensive sentinel node biopsy. Risk factors included wound infection, older age, higher body mass index, and radiation therapy.8PubMed Central. Incidence of lower limb lymphedema after vulvar cancer A systematic review and meta-analysis Lymphedema causes chronic swelling, heaviness, tightness, and sometimes pain in the affected leg, and it can persist for years.
On the more hopeful side, reconstructive techniques such as fascio-cutaneous gluteal flaps can restore tissue coverage and, in some cases, restore sensation to the surgical area within months.9PubMed. Vulvar reconstruction using a “V-Y” fascio-cutaneous gluteal flap: a valid reconstructive alternative in post-oncological loss of substance
Radiation and Chemoradiation
Radiation therapy, used either as the primary treatment or after surgery, is essential for many vulvar cancers but comes with its own pain burden. It can cause chronic pain, sexual dysfunction, infections, and delayed wound healing. Acute radiation dermatitis is a near-universal side effect in the treatment area, producing raw, blistered, and sometimes ulcerated skin in the vulvar and groin regions.10Gynecologic Oncology Reports. Insights from plastic and reconstructive surgery wound specialists in managing complex vaginal and vulvar toxicities following radiation therapy When chemotherapy is given alongside radiation, these tissue effects tend to be more severe.
Sexual Function After Treatment
The impact of vulvar cancer treatment on sexual function is substantial and underappreciated. Surgery alters the anatomy of the vulva, and depending on how much tissue is removed, the changes can profoundly affect sensation and the ability to experience pleasure.
A study of 42 women treated for pre-invasive vulvar cancer found a specific pattern of sexual disruption. Desire was maintained, but the excitement and resolution phases of sexual response were significantly impaired, and orgasm was affected to a lesser extent. There was a two- to three-fold increase in sexual dysfunction compared to before treatment, and 30% of the women were sexually inactive at follow-up. The severity of dysfunction correlated with how extensive the surgery was.11PubMed Central. Sexual functioning after treatment of in situ vulvar cancer: preliminary report
For invasive cancer, the picture is worse. A prospective controlled study found that patients with vulvar cancer reported significantly more sexual dysfunction than healthy controls both before and after surgery, including painful intercourse at entry and at depth, abdominal pain during sex, reduced ability to reach orgasm, and reduced orgasm intensity.12International Journal of Gynecological Cancer. Psychologic, Relational, and Sexual Functioning in Women After Surgical Treatment of Vulvar Malignancy: A Prospective Controlled Study A literature review covering the broader body of research confirmed that women who undergo surgical treatment for vulvar cancer are at high risk for sexual dysfunction, dissatisfaction with their partner relationship, and psychological difficulties. Factors that increased the risk included older age, poor general well-being, history of depression or anxiety, and larger excisions.13The Journal of Sexual Medicine. Sexual, Psychological, and Relational Functioning in Women After Surgical Treatment for Vulvar Malignancy: A Literature Review
These findings suggest that pain during sex after vulvar cancer treatment is not just a side effect to manage but a central quality-of-life issue that needs to be part of treatment planning from the start.
HPV-Positive Versus HPV-Negative Subtypes
Vulvar squamous cell carcinoma, the most common type, comes in two biologically distinct forms defined by whether the tumor is driven by human papillomavirus. HPV-positive tumors and HPV-negative tumors show distinct gene expression patterns, including differences in circular RNAs previously linked to other cancers.14PubMed Central. Human Papillomavirus‒Positive and ‒Negative Vulvar Squamous Cell Carcinoma Are Biologically but Not Clinically Distinct
The practical importance for patients is that the subtypes carry different prognoses. Research classifying tumors into three molecular groups found that the HPV-negative subtype with mutated p53 had the worst outcomes, with roughly three to four times the risk of disease recurrence and death compared to the other groups. HPV-positive tumors had the most favorable outcomes.15PubMed. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes The HPV-negative/p53-mutant subtype tends to arise in older women, often on a background of lichen sclerosus, while the HPV-positive subtype more frequently occurs in younger women and is linked to conditions like vulvar intraepithelial neoplasia.
Why does this matter for pain? Indirectly, the subtype affects how aggressively the cancer behaves and therefore how likely it is to progress to a stage where pain becomes prominent. It also affects treatment decisions and the likelihood of recurrence, which carries its own pain implications.
Palliative Care for Advanced Vulvar Cancer
For women with advanced or recurrent vulvar cancer, the focus often shifts toward symptom management. Advanced vulvar tumors can cause a distressing combination of pain, itching, foul-smelling discharge, bleeding, and difficulty with basic functions like sitting and urinating. Palliative care teams play a critical role in managing these symptoms, helping avoid unnecessary hospitalizations, and supporting patients to die at home without uncontrolled pain and other symptoms when that is their preference.16PubMed. Role of palliative care intervention in patients with vulvar cancer: a retrospective study
Newer palliative options are being explored as well. Electrochemotherapy, which combines low-dose chemotherapy with localized electrical pulses to increase drug uptake in tumor tissue, has been studied as a symptom-oriented treatment for locally advanced or recurrent vulvar cancer. In a small exploratory study, the procedure was well tolerated and helped manage pain, itching, odor, and secretion in patients for whom standard curative treatment was no longer an option.17PubMed Central. Electrochemotherapy as a symptom-oriented palliative treatment option: an exploratory single-center study in 15 patients with locally advanced or locoregionally recurrent vulvar carcinoma
Pain management in advanced vulvar cancer often requires a multimodal approach. Standard analgesics work reasonably well for somatic pain from tumor bulk. Neuropathic pain, as noted earlier, typically requires medications originally developed for nerve conditions, such as gabapentinoids or certain antidepressants. Some patients benefit from nerve blocks or intrathecal drug delivery when oral medications are not enough.
Survival Rates by Stage and Age
Prognosis in vulvar cancer depends heavily on how early the disease is caught. A large German retrospective study reported an overall five-year survival rate of about 70%. But that average obscures a dramatic range. Five-year relative survival was about 92% for Stage I disease but dropped to roughly 21% for Stage IVB. Age mattered too: women under 55 had about 89% five-year relative survival, while those over 75 had about 68%. Lymph node involvement and tumor size were the strongest independent predictors of survival.18PubMed Central. Influence of stage and age on survival of patients with vulvar cancer in Germany: a retrospective study
These numbers reinforce a central theme: early detection transforms outcomes. A Stage I tumor found because someone took persistent itching seriously has a very different trajectory than a Stage III or IV cancer diagnosed after months of misattributed symptoms. The fact that most early vulvar cancers present with itching rather than pain makes awareness all the more important, because people tend to act on pain and tolerate itching.
Young Women and Vulvar Cancer
Although vulvar cancer is predominantly a disease of older women, it does occur in younger patients, and their experience sometimes differs. In a study of young women with vulvar cancer, about 58% presented with Stage I disease, and 77% were tobacco smokers. Among those with advanced disease, about 40% had a history of HPV exposure and roughly 47% had vulvar intraepithelial neoplasia.19PubMed Central. Vulvar cancer in young women: demographic features and outcome evaluation Symptoms had been present for over a year in nearly half the participants, yet that delay did not correlate with worse staging, suggesting that the biology of the tumor mattered more than the time to diagnosis in this particular group.
Younger patients may face unique psychosocial challenges around pain and sexual function. They are more likely to be sexually active and to prioritize fertility and body image, which makes the physical and emotional aftermath of treatment especially burdensome. The research on sexual functioning consistently identifies larger excision size as a predictor of worse outcomes, which creates a tension between adequate cancer removal and preservation of anatomy in women who may have decades of sexual life ahead of them.